Clinical trials: Gastroparesis
Idiopathic Gastroparesis, Diabetic Gastroparesis
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT06836557
- Testing
- Tradipitant
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 17 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Gastroparesis
Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms
The primary objective of the study is to evaluate how patients with gastroparesis interpret the instructions, item content, and response options of a daily diary questionnaire designed to assess the key symptoms of gastroparesis.
- Trial name
- NCT01316484
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
Gastroparesis, also referred to as delayed gastric emptying, is a debilitating, chronic disorder that slows or stops the passage of food from the stomach to the small intestine.
- Trial name
- NCT02187094
- Testing
- TC-6499
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Targacept Inc.
Diabetic Gastroparesis
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
To determine whether a new Orally Disintegrating Tablet of Reglan (metoclopramide) is metabolized faster than the conventional Reglan tablet in patients with diabetic gastroparesis, pharmacokinetics following a single 10 mg dose…
- Trial name
- NCT00139893
- Testing
- Reglan ODT
- Where
- United States
- Sponsor
- UCB Pharma
Gastroparesis, Diabetes Mellitus, Type 1
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily…
- Conditions
- Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01452815
- Testing
- 10mg TZP-102, 20mg TZP-102
- Where
- 52 sites in United States, Belgium and 6 more
- Volunteers
- 201 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Slow Transit Constipation
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
The study objective is to demonstrate the equivalence of the Atmo Motility Gas Capsule System with the predicate SmartPill in measuring gastric emptying time and colonic transit time through examination of device agreement.
- Conditions
- Gastroparesis, Slow Transit Constipation, IBS
- Trial name
- NCT05718505
- Testing
- Atmo Motility Gas Capsule System, SmartPill Monitoring System
- Where
- 2 sites in United States
- Volunteers
- 209 people
- Sponsor
- Atmo Biosciences Pty Ltd
Gastroparesis
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and…
- Trial name
- NCT01039805
- Testing
- GSK962040 (50 mg), GSK962040 (75 mg)
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Gastroparesis, Slow Transit
Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients
This study will compare gastrointestinal transit time measured by the SmartPill and the Atmo gas capsule in patients with gastrointestinal motility disorders.
- Trial name
- NCT04977063
- Testing
- Atmo gas capsule, SmartPill
- Where
- 3 sites in Australia
- Volunteers
- 53 people
- Sponsor
- Atmo Biosciences Pty Ltd
Gastroparesis
An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options
The purpose of this study is to assess the effectiveness of cisapride in patients with a primary diagnosis of chronic gastroparesis (a stomach disorder) of unknown cause.
- Trial name
- NCT01281540
- Testing
- Cisapride
- Volunteers
- 20 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastroparesis, Gastroparesis Nondiabetic
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- RESTING (NCT05980455)
- Testing
- Enterra® Therapy System
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Gastroparesis
Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis
This protocol is designed to validate use of the SPM for diagnosis of delayed gastric emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study on patient management in the gastroparetic…
- Trial name
- NCT02022826
- Testing
- SmartPill Monitoring System
- Where
- 11 sites in United States
- Volunteers
- 167 people
- Sponsor
- Medtronic - MITG